IGF1R and breast cancer: Numerous clinical and experimental data indicated that IGF-IR is overexpressed in several subtypes of breast cancer (83), and many conditions lead to the activation of IGF-IR tyrosine kinase activity (84), allowing interaction with its main substrates, such as insulin receptor substrates (IRS) and the Src-homology-2-containing protein SH2 (SHC) (74).